| Literature DB >> 29296934 |
Yuya Yoshioka1,2, Tatsuaki Mizutani1, Satoshi Mizuta3, Ayumi Miyamoto1,2, Satoru Murata1, Toshiaki Ano1,2, Hiroshi Ichise1, Daisuke Morita1,2, Hiroyuki Yamada4, Yoshihiko Hoshino5, Tatsuaki Tsuruyama6, Masahiko Sugita1,2.
Abstract
Macrophages have the potential to undergo cellular transformation into epithelioid cells, and their concentric accumulation in tissues results in the development of granulomas. Although epithelioid cells are an essential and dominant component of granulomas, other cell types have also been detected, which may contribute to the establishment of well-organized granulomas, as observed in human granulomatous diseases. We herein demonstrated that neutrophils may mediate these functions. By taking advantage of the guinea pig pulmonary granuloma model, we obtained a rat monoclonal antibody with unique reactivity to granuloma cells. This antibody, termed G213, reacted with clusters of neutrophils located in the central area of granulomas, and a biochemical analysis identified the G213-reactive antigen as S100A9, a calcium-binding protein of the S100 family, which was expressed abundantly in neutrophils. Consistent with the multifaceted functions attributed to S100A9, including its role in neutrophil extravasation and macrophage activation, the blockade of S100A9 functions with the specific inhibitor, tasquinimod, impaired the formation of organized granulomas with neutrophil cores. These results demonstrate the critical role of neutrophils and the S100A9 protein in granuloma formation. Because intragranuloma S100A9+ neutrophils were also detected in humans, these results indicate the potential of tasquinimod, a new anticancer drug candidate, for manipulating human granulomatous diseases.Entities:
Year: 2016 PMID: 29296934 PMCID: PMC5737174 DOI: 10.1182/bloodadvances.2016000497
Source DB: PubMed Journal: Blood Adv ISSN: 2473-9529